Skip to content

Aclaris Therapeutics

US · ACRS #3750 by market cap Listed 2015
3.40 -0.30 -8.11%
Live - 5344 symbols - heartbeat 374s ago · 2026-10-08 09:10
Pre-market 3.25 -4.38%
After-hours 3.46 +1.76%
Overnight 3.39 -0.29%
Market cap
500.48M
P/B
4.02
EPS
-0.53
Reader sentiment Are you bullish or bearish on ACRS?

Anonymous reader poll. Unscientific, not investment advice.

Shares of Aclaris Therapeutics closed at 3.40, down 8.11%. That leaves the company valued at approximately 500.48M, the #3750 most valuable US-listed company we track. Wall Street's 5-analyst consensus lands on Buy, with a price target averaging 12.00 (+253% from here). Against a 52-week band of 1.74-6.60, the shares are currently 34% of the way up.

✦ StockVane Quant Insights how this is computed

Quant Rating B Preliminary
  • Not yet in the StockVane Momentum strategy's universe - this name needs price history back to 2021 for a reliable signal and doesn't have it yet (most often because it IPO'd or was spun off more recently). This grade is a preliminary blend of valuation, momentum and analyst data, not a Momentum buy/sell call.
  • Price momentum averages +22.6% across the trailing 3-month/1-year windows.
  • Analyst consensus across 5 analysts is Buy.
Quant Sentiment Neutral
  • Recent price momentum is +22.6% on average (3-month/1-year).
  • Main-fund capital flow has been a net inflow over the last 45 sessions.
  • Short interest has risen to 10.9% of float.
  • Analyst tilt is Buy.
Quant Technical Outlook Bearish
  • Price is below its 20-day average and below its 60-day average.
  • The 20-day average is below the 60-day average, a short-term downtrend.

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Price chart

6.543.403.402026-04-092026-10-07
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60

Performance

1W -35.36%
1M -44.89%
3M -39.50%
6M -9.33%
YTD +12.96%
1Y +84.78%
3Y -43.89%
5Y -81.48%

Key statistics

Price & volume

Prev close
3.70
Open
3.60
Day range
3.32 - 3.62
Avg price
3.41
Volume
9.00M
Turnover
30.71M
Amplitude
8.24%
52-week range
1.74 - 6.60

Valuation

P/E
-6.42
P/E (TTM)
-5.86
P/B
4.02
EPS
-0.53
Net profit
-78.02M
Net assets
124.53M

Share structure

Market cap
500.48M
Float cap
343.98M
Shares out
147.20M
Float shares
101.17M

Dividend & listing

Dividend (TTM)
0.00
Listing date
2015-10-07
52-week range 34% of range
1.74 6.60

48.5% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

+4.62M net over the window

Short interest

Shares short
16.08M
As of
2026-09-15

Frequently asked questions

What is the current stock price of Aclaris Therapeutics (ACRS)?

Aclaris Therapeutics last traded at 3.40. The quote on this page refreshes every few seconds while US markets are open.

What is Aclaris Therapeutics's market cap?

About 500.48M.

What is the P/E ratio of Aclaris Therapeutics?

The trailing twelve-month P/E is -5.86. The Valuation tab shows it against the stock's own five-year range.

Does Aclaris Therapeutics pay a dividend?

Aclaris Therapeutics does not currently pay a regular dividend.

Is Aclaris Therapeutics a buy according to analysts?

The consensus of 5 analysts is a Buy rating, with an average 12-month price target of 12.00, which implies 252.9% upside from the current price. This is not investment advice.

Quote time 2026-10-08 09:10:00 · For reference only, not investment advice and not tailored to your situation.